Mosnaim A D, Huprikar S, Wolf M E, Diamond S
Department of Pharmacology and Molecular Biology, University of Health Sciences, Chicago Medical School, Illinois 60064.
Headache. 1990 Jul;30(8):488-90. doi: 10.1111/j.1526-4610.1990.hed3008488.x.
Platelet monoamine oxidase activity (MAO) in a group (n = 17) of white, female migraineurs during an acute migraine attack was similar to both the values obtained for the same group of patients two to three weeks after the headache episode (pain-free period) and to the results obtained for a group (n = 18) of sex and race-matched, age-comparable, drug-free healthy volunteers (blind study; substrate p-tyramine, 38.7 +/- 5.7, 41.9 +/- 8.8 and 43.0 +/- 3.4 or p-methoxybenzylamine, 178.9 +/- 11.3, 177.2 +/- 6.9 and 181.0 +/- 9.7 nmole/hr/10(9) platelets +/- SD respectively). With each patient serving as its own control, MAO activity during the migraine episode and when pain-free failed to show a significant trend. Neither a number of other medical conditions nor the use of several medications appeared to significantly influence our results. The present work, while dealing only with a small but well defined patient population, argues against the possible usefulness of platelet MAO activity as a biological marker for migraine headaches.
一组(n = 17)患有偏头痛的白人女性在急性偏头痛发作期间的血小板单胺氧化酶活性(MAO),与该组患者在头痛发作两到三周后(无痛期)获得的值以及一组(n = 18)性别、种族匹配、年龄相仿且未用药的健康志愿者(盲法研究;底物对酪胺,分别为38.7 +/- 5.7、41.9 +/- 8.8和43.0 +/- 3.4,或对甲氧基苄胺,分别为178.9 +/- 11.3、177.2 +/- 6.9和181.0 +/- 9.7纳摩尔/小时/10⁹血小板 +/- 标准差)获得的结果相似。以每位患者自身作为对照,偏头痛发作期间和无痛时的MAO活性未显示出显著趋势。一些其他医疗状况和多种药物的使用似乎均未对我们的结果产生显著影响。本研究虽然仅涉及一小群定义明确的患者,但反对将血小板MAO活性作为偏头痛生物学标志物的潜在用途。